Policy & Regulation
US Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Programme with Three New Phase 3 Trials
15 February 2019 - - US-based biopharmaceutical company Merck (NYSE: MRK) has presented interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating Keytruda, Merck's anti-PD-1 thera...
Affinivax Initiates Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas
15 February 2019 - - The first subject has been dosed with ASP3772, US-based Affinivax, Inc.'s novel MAPS vaccine targeting Streptococcus pneumoniae (pneumococcus), the company said.
Spring Pharmaceutical Group posts higher net income of USD12.91m for the nine months ended 31 December 2018
15 February 2019 - Health care supplement products Spring Pharmaceutical Group Inc (OTCQB:CYIG) stated on Thursday its net income of USD12.91m (USD0.43 per basic and diluted share) for the nine months...
Tanabe Research Laboratories USA Inc files first IND application with the US FDA for phase I trial of TR1801-ADC in cMet positive solid tumours patients
15 February 2019 - Tanabe Research Laboratories USA Inc (TRL) revealed on Thursday that it has successfully submitted its first Investigational New Drug (IND) application with the US Food and Drug adm...
Moderna touts Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
14 February 2019 - - US-based biotechnology company Moderna, Inc., (NASDAQ: MRNA) has received topline data from the first planned interim analysis of safety and immunogenicity from its Phase 1 study ...
Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
14 February 2019 - - US-based biotechnology company Exelixis, Inc. (NASDAQ: EXEL) is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the c...